Enabling the Future of Oligo Therapeutics

Current manufacturing processes are unsustainable for future demand:

>4300 kg of waste per kg of RNA - limiting capacity

High manufacturing costs - limit access

Process variability when scaling - clinical translation risk

Inconsistent purification for long/heavily modified RNA - performance risk

GemBio's proprietary manufacturing platform is designed to enable mass adoption of oligonucleotide medicines.‍

Designed for scalability, it delivers greater production capacity compared to conventional methods, enabling more doses per year, reducing production bottlenecks.

Powered by our ClarityCapture™ purification technology, our resin-free manufacturing platform delivers exceptional performance and high-purity products with consistent CMC profiles across all scales.

We work closely with therapeutic developers to reduce clinical translation risks and accelerate their path to the clinic.